Microcap Ledger Sight Sciences, Inc. $SGHT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Menlo Park, CA
- Fiscal year end
- December 31
- Shares outstanding
- 55,087,990 [10-Q 2026-08-05]
What the company doesAI summary of filing
Sight Sciences develops and sells medical devices for treating glaucoma and dry eye disease. The company's interventional glaucoma segment offers OMNI Surgical System and SION Surgical Instrument, which enable minimally invasive procedures to reduce intraocular pressure in patients with primary open-angle glaucoma; these products are sold primarily to ambulatory surgery centers and hospital outpatient departments in the U.S. and select European markets. The interventional dry eye segment offers the TearCare system, a heat-based therapeutic device designed to treat meibomian gland disease, sold primarily to optometry and ophthalmology practices in the U.S. Sight Sciences is revenue-generating, with sales driven by procedure adoption and third-party reimbursement from Medicare and private insurers. [10-K 2026-03-04]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $43.09M | −$17.43M | −$12.69M | $79.75M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | $77.36M | −$38.43M | −$29.69M | $91.97M | [10-K 2026-03-04] |
| FY ended Dec 2024 | $79.87M | −$51.51M | −$22.35M | $120.36M | [10-K 2026-03-04] |
- Quarterly cash burn
- −$6.35M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 50,754,616 | [10-Q 2024-11-07] |
| 2025-02-27 | 51,332,694 | [10-K 2025-03-07] |
| 2025-05-02 | 51,702,088 | [10-Q 2025-05-08] |
| 2025-08-01 | 52,367,359 | [10-Q 2025-08-07] |
| 2025-10-31 | 52,871,731 | [10-Q 2025-11-06] |
| 2026-02-26 | 54,005,984 | [10-K 2026-03-04] |
| 2026-04-30 | 54,409,942 | [10-Q 2026-05-06] |
| 2026-07-31 | 55,087,990 | [10-Q 2026-08-05] |
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-02 | Taylor Brenton | sell | 2,988 | $8.85 | [4 2026-10-05] |
| 2026-10-02 | Bauerlein Alison | sell | 25,260 | $8.85 | [4 2026-10-05] |
| 2026-10-02 | Rodberg James | sell | 7,208 | $8.85 | [4 2026-10-05] |
| 2026-10-01 | Badawi David | sell | 7,797 | $9.05 | [4 2026-10-05] |
| 2026-10-01 | Badawi Paul | sell | 29,653 | $9.05 | [4 2026-10-05] |
| 2026-08-10 | Rashid Kashif | grant | 181,818 | — | [4 2026-08-18] |
| 2026-07-06 | Hayden Jeremy B. | sell | 12,733 | $5.51 | [4 2026-07-06] |
| 2026-07-02 | Rodberg James | sell | 6,902 | $5.36 | [4 2026-07-06] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-10 | 8-K | Director or officer change |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-06-05 | 8-K | Shareholder vote results |
| 2026-05-06 | 10-Q | Quarterly report |
| 2026-05-06 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-04-23 | 8-K | Regulation FD disclosure |
| 2026-04-22 | DEF 14A | Proxy statement |
| 2026-04-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-03-30 | 8-K | Regulation FD disclosure |
| 2026-03-04 | 10-K | Annual report |
| 2026-03-04 | 8-K | Results of operations; Regulation FD disclosure |
Alerts for $SGHT
Email me when Sight Sciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.